312 related articles for article (PubMed ID: 32855769)
1. Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation.
Zhang Y; Tao C; Xuan C; Jiang J; Cao W
Oxid Med Cell Longev; 2020; 2020():9542165. PubMed ID: 32855769
[TBL] [Abstract][Full Text] [Related]
2. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats.
Chen J; Chen Y; Luo Y; Gui D; Huang J; He D
Eur J Pharmacol; 2014 Aug; 736():86-94. PubMed ID: 24809932
[TBL] [Abstract][Full Text] [Related]
3. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression.
Gui D; Huang J; Guo Y; Chen J; Chen Y; Xiao W; Liu X; Wang N
Cytokine; 2013 Mar; 61(3):970-7. PubMed ID: 23434274
[TBL] [Abstract][Full Text] [Related]
4. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
Wang ZS; Xiong F; Xie XH; Chen D; Pan JH; Cheng L
BMC Nephrol; 2015 Mar; 16():44. PubMed ID: 25886386
[TBL] [Abstract][Full Text] [Related]
5. Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats.
Fan Y; Fan H; Zhu B; Zhou Y; Liu Q; Li P
BMC Complement Altern Med; 2019 Dec; 19(1):355. PubMed ID: 31805910
[TBL] [Abstract][Full Text] [Related]
6. Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats.
Lei X; Zhang L; Li Z; Ren J
Drug Des Devel Ther; 2018; 12():2785-2793. PubMed ID: 30233141
[TBL] [Abstract][Full Text] [Related]
7. Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy.
Wang E; Wang L; Ding R; Zhai M; Ge R; Zhou P; Wang T; Fang H; Wang J; Huang J
Pharmacol Res; 2020 Jul; 157():104831. PubMed ID: 32339782
[TBL] [Abstract][Full Text] [Related]
8. Combination of Ginsenoside Rg1 and Astragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy.
Du N; Xu Z; Gao M; Liu P; Sun B; Cao X
Drug Des Devel Ther; 2018; 12():3517-3524. PubMed ID: 30425453
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of Astragaloside IV on endoplasmic reticulum stress-induced renal tubular epithelial cells apoptosis in type 2 diabetic nephropathy rats.
Ju Y; Su Y; Chen Q; Ma K; Ji T; Wang Z; Li W; Li W
Biomed Pharmacother; 2019 Jan; 109():84-92. PubMed ID: 30396095
[TBL] [Abstract][Full Text] [Related]
10. Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice.
Song G; Han P; Sun H; Shao M; Yu X; Wang W; Wang D; Yi W; Ge N; Li S; Yi T
J Int Med Res; 2018 Jul; 46(7):2883-2897. PubMed ID: 29896981
[TBL] [Abstract][Full Text] [Related]
11. Phenethyl isothiocyanate attenuates diabetic nephropathy via modulation of glycative/oxidative/inflammatory signaling in diabetic rats.
Eisa NH; Khodir AE; El-Sherbiny M; Elsherbiny NM; Said E
Biomed Pharmacother; 2021 Oct; 142():111666. PubMed ID: 34215478
[TBL] [Abstract][Full Text] [Related]
12. Astragaloside IV ameliorates diabetic nephropathy in
Feng H; Zhu X; Tang Y; Fu S; Kong B; Liu X
Int J Mol Med; 2021 Aug; 48(2):. PubMed ID: 34278447
[TBL] [Abstract][Full Text] [Related]
13. Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy.
Xing L; Fang J; Zhu B; Wang L; Chen J; Wang Y; Huang J; Wang H; Yao X
Life Sci; 2021 Mar; 269():119068. PubMed ID: 33476631
[TBL] [Abstract][Full Text] [Related]
14. Fucoidan exerts protective effects against diabetic nephropathy related to spontaneous diabetes through the NF-κB signaling pathway in vivo and in vitro.
Wang Y; Nie M; Lu Y; Wang R; Li J; Yang B; Xia M; Zhang H; Li X
Int J Mol Med; 2015 Apr; 35(4):1067-73. PubMed ID: 25672488
[TBL] [Abstract][Full Text] [Related]
15. Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway.
Chen YJ; Kong L; Tang ZZ; Zhang YM; Liu Y; Wang TY; Liu YW
Biomed Pharmacother; 2019 Mar; 111():1166-1175. PubMed ID: 30841430
[TBL] [Abstract][Full Text] [Related]
16. Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway.
Lei X; Zhang BD; Ren JG; Luo FL
Life Sci; 2018 Aug; 206():77-83. PubMed ID: 29792879
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of Astragalus saponin I on early stage of diabetic nephropathy in rats.
Yin X; Zhang Y; Wu H; Zhu X; Zheng X; Jiang S; Zhuo H; Shen J; Li L; Qiu J
J Pharmacol Sci; 2004 Jun; 95(2):256-66. PubMed ID: 15215651
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of Angiopoietin-Like Protein 2 Ameliorates Diabetic Nephropathy by Inhibiting TLR4.
Yang S; Zhang J; Wang S; Shi J; Zhao X
Cell Physiol Biochem; 2017; 43(2):685-696. PubMed ID: 28946139
[TBL] [Abstract][Full Text] [Related]
19. Mitogen-activating protein kinase kinase kinase kinase-3, inhibited by Astragaloside IV through H3 lysine 4 monomethylation, promotes the progression of diabetic nephropathy by inducing apoptosis.
Fan Y; Fan H; Li P; Liu Q; Huang L; Zhou Y
Bioengineered; 2022 May; 13(5):11517-11529. PubMed ID: 35510516
[TBL] [Abstract][Full Text] [Related]
20. Ursolic acid improves diabetic nephropathy via suppression of oxidative stress and inflammation in streptozotocin-induced rats.
Xu HL; Wang XT; Cheng Y; Zhao JG; Zhou YJ; Yang JJ; Qi MY
Biomed Pharmacother; 2018 Sep; 105():915-921. PubMed ID: 30021385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
